Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program
China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...
Drug
Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer
The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...
Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials
China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...
Kintor’s KX-826 Reaches Primary Endpoint in Phase II Study for Female AGA
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced that the Phase II clinical study for its...
Simcere’s Edaravone, Borneol Sublingual Tablets Reach Phase III Efficacy Endpoint
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that a Phase III clinical study for...
ImmuneOnco Initiates Phase II Clinical Study for CD47 Antibody IMM01
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the initiation of a Phase II clinical study...
Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China
China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...
Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...
CSL Vifor and Fresenius Kabi Win China Approval for Ferinject
Swiss firm CSL Vifor and Germany’s Fresenius Kabi have announced the first regulatory approval in...
Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study
China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...
Clover Biopharmaceuticals’ SCB-2019 Vaccine Reduces Household Transmission of COVID-19
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced that Clinical Infectious Diseases has published...
Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...
Ascletis Pharma’s COVID-19 Drug Candidate ASC11 Accepted for Review by NMPA
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its Investigational New Drug (IND) filing...
Luye Pharma Initiates Phase II Study for LY 03014 in China
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...
Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment
US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...
Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment
China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...